Peer Support Workers Study
Creating Safety in Chaos: Integrating Peer Support Workers in Emergency Departments to Support Patients Who Use Substances and Opioids
Many people with high-risk opioid use visit emergency departments (EDs), facing a high risk of death if they leave before completing care. Peer support workers (Peers) - people with lived experience of substance use - may improve patient comfort, reduce early departures, and potentially lower mortality rates. This study aims to evaluate how a hospital-implemented ED Peer program can enhance patient support, reduce barriers to care, and provide harm-reduction resources in a person-centred and trauma-informed manner. The study will assess whether Peer availability and direct Peer-patient interactions are associated with improved ED care outcomes, including reduced leaving before treatment completion, as well as subsequent healthcare utilization, overdose, mortality, and other relevant patient outcomes.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The study was initially designed as a feasibility evaluation of the ED Peer program and of the use of a randomized shift schedule to assign Peer availability. As program implementation progressed and staffing stabilized, the evaluation framework was refined to examine both the effect of Peer availability and outcomes associated with direct Peer-patient interaction.
From 23 November 2024 through 16 October 2025, Peer availability was assigned according to an a priori randomized shift schedule developed in collaboration with human resources and ED operational leadership. Following achievement of full Peer staffing, the program transitioned to routine clinical operation.
The study has two main analytic objectives: 1) during the shift-randomization period, investigators will compare outcomes between shifts with and without scheduled Peer availability among patients presenting with substance use-related concerns; 2) investigators will evaluate outcomes associated with direct Peer-patient interaction by comparing patients who interacted with a Peer with comparable patients who did not interact with a Peer.
The primary outcome is leaving before treatment completion (LBTC). Additional outcomes will include measures of ED care, subsequent healthcare utilization, substance use treatment, overdose, mortality, and other relevant clinical and health-service outcomes.
Investigators will request routinely collected records for Vancouver General Hospital ED visits during the study period. Records of eligible ED patients presenting during the study period will be linked to provincial administrative data to evaluate outcomes. Data sources will include the National Ambulatory Care Reporting System (NACRS), Discharge Abstract Database (DAD), Vital Statistics, PharmaNet, Medical Services Plan (MSP), and the Central Demographics File. Population Data BC and Health Data Platform BC will support secure data linkage, and additional relevant datasets may be explored where useful to the study objectives.
These data will support cohort definition, construction of comparison groups, development of propensity scores, sensitivity analyses, and evaluation of outcomes including receipt of ED treatments and referrals, ED revisits, hospitalizations, overdose, opioid agonist therapies and other addiction treatments, mortality, and other relevant health-service outcomes.
Investigators will also obtain records of security-related events occurring during ED visits over the study period. These data will be used to examine whether Peer availability is associated with differences in events such as need for de-escalation or other security involvement.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Elle Wang, MSc
- Numero di telefono: 604-615-2538
- Email: elle.wang@ubc.ca
Backup dei contatti dello studio
- Nome: Cindy Liu, BSc
- Numero di telefono: 778-929-1281
- Email: cindy.q.liu@ubc.ca
Luoghi di studio
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Reclutamento
- Vancouver General Hospital
-
Contatto:
- Jessica Moe, MD
- Email: jessica.moe@ubc.ca
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Emergency Department (ED) patient at Vancouver General Hospital (VGH)
- Age 18 years or older
- Identified as using substances
- Able to receive or decline peer support services during the ED visit
Exclusion Criteria:
- Under 18 years of age
- Does not report substance use
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Peer Support Intervention
Investigators will evaluate the Peer Support intervention using two analytical approaches:
|
During intervention shifts, Peer support workers were scheduled to be available in the emergency department to provide support to patients with substance use-related concerns. Peer support workers offered services tailored to individual patients' needs, including referrals to clinical and social support services (e.g., social work, addictions specialists, Indigenous patient navigators, and community-based addiction services), provision of resources (e.g., blankets, food, naloxone kits, sterile drug use supplies, and information brochures), emotional support, and communication support between patients and healthcare providers regarding patients' conditions and ED care. The primary analysis will evaluate the effect of randomized Peer availability using an intention-to-treat approach. The secondary analysis will evaluate outcomes associated with actual Peer-patient interactions by comparing patients who received Peer support with comparable patients who did not. |
|
Nessun intervento: No Peer Support Intervention
Investigators will define the comparison group using two approaches:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Leaving Before Treatment Completion (LBTC)
Lasso di tempo: From enrollment through 12 months of follow-up
|
Investigators will measure LBTC among ED patients with substance use-related complaints (e.g., substance withdrawal, misuse/intoxication, overdose, and localized swelling/redness). Investigators will evaluate LBTC using two approaches:
|
From enrollment through 12 months of follow-up
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Distribution of randomized Peer shifts by day of week (feasibility outcome)
Lasso di tempo: From study initiation to achievement of full Peer staffing, approximately one year
|
Assessed by examining the distribution of scheduled Peer shifts across each day of the week over the 48-week randomized schedule period. The schedule was developed in collaboration with human resources and ED operational leadership and approved as meeting hospital employee policy. The randomization approach used block-based scheduling with built-in constraints (e.g., mandatory weekends off). This outcome evaluates whether the resulting schedule achieved a balanced weekday/weekend distribution. Unit of Measure: Number and percentage of Peer shifts scheduled per day of the week |
From study initiation to achievement of full Peer staffing, approximately one year
|
|
ED-based substance use and harm reduction interventions
Lasso di tempo: Baseline
|
Secondary outcomes will include receipt of naloxone kits, opioid agonist therapy doses, and withdrawal treatments during the ED visit. Investigators will compare counts of these outcomes between intervention (Peer) and control (no Peer) groups using multivariable count regression. Investigators will assess clustering of outcomes by shift and adjust for the same covariates included in the primary analysis. |
Baseline
|
|
30-day health care utilization and clinical events (e.g., drug poisoning, mortality)
Lasso di tempo: From enrollment through 30 days of follow-up from ED visit
|
Exploratory outcomes will include ED visits, hospitalizations, drug poisoning, and mortality within 30 days following the index ED visit. Investigators will analyze counts of these events using multivariable count regression, with the log-transformed length of follow-up included as an offset term where applicable, and will conduct time-to-event analyses using Cox regression. Investigators will assess clustering of outcomes by shift and adjust for the same covariates included in the primary analysis. |
From enrollment through 30 days of follow-up from ED visit
|
|
Security-related events during ED visits
Lasso di tempo: Baseline
|
Investigators will obtain records of security-related events occurring during ED visits over the study period from the ED security event database. Investigators will assess whether Peer availability was associated with differences in the frequency and type of security-related events, including escalation events and incidents requiring security involvement. |
Baseline
|
|
Thematic summary of Indigenous patients' experiences with the Peer program
Lasso di tempo: Within 6 months after the patient's ED visit involving Peer interaction
|
Indigenous patient perspectives on the Peer program will be collected through surveys, culturally grounded storytelling and sharing circles. Sessions will be guided by open-ended questions to explore perceived safety, support, and emotional impact of Peer involvement in the emergency department. Transcripts will be analyzed using Indigenous-informed thematic analysis to identify key insights and priorities for culturally safe care. Unit of Measure: Themes and narratives identified through qualitative analysis |
Within 6 months after the patient's ED visit involving Peer interaction
|
|
Thematic summary of healthcare providers' perceptions of the Peer program assessed through focus groups
Lasso di tempo: From 12-24 months after Peer program implementation
|
Acceptability of the Peer program among healthcare providers will be evaluated using semi-structured focus groups conducted periodically post-implementation. Discussions will explore perceived value, observed patient impact, integration into ED workflows, challenges, and suggestions for improvement. Audio recordings will be transcribed and analyzed using thematic content analysis to identify recurring patterns and representative quotes. Unit of Measure: Thematic categories identified through qualitative analysis |
From 12-24 months after Peer program implementation
|
|
Thematic summary of PWLLE perceptions and experiences of the Peer program assessed through focus groups
Lasso di tempo: From 12-24 months after Peer program implementation
|
Perspectives of people with lived and living experience (PWLLE) on the Peer program will be evaluated using semi-structured focus groups. Discussions will explore participants' perceptions of the value and accessibility of Peer support, experiences of substance use-related care in the ED, perceived impacts of the Peer program, barriers and gaps in care, and suggestions for improving Peer support and program delivery. Audio recordings will be transcribed and analyzed using thematic content analysis to identify recurring themes and representative quotes. Unit of Measure: Thematic categories identified through qualitative analysis |
From 12-24 months after Peer program implementation
|
|
Acceptability of the Peer program evaluated through periodic surveys
Lasso di tempo: From 12-24 months after Peer program implementation
|
Acceptability and implementation of the Peer program will be assessed through periodic surveys administered to Peers, patients accessing Peer services, members of the ED buprenorphine/naloxone team, and multidisciplinary healthcare providers. Surveys will assess experiences with the Peer program, including perceived value, respect, ease of communication, clarity of information, comfort, confidentiality, teamwork, integration into ED workflows, and perceived facilitators and barriers to implementation. |
From 12-24 months after Peer program implementation
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Jessica Moe, MD, University of British Columbia
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- H24-03008
- F26-03530 (Altro numero di sovvenzione/finanziamento: Health Canada)
- F25-02658 (Altro numero di sovvenzione/finanziamento: Vancouver Coastal Health Research Institute)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
There is no plan to make individual participant data available to other researchers
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .